You can buy Ivesa at the lowest price in the online pharmacy Nextgen.ooo . Furmonertinib, a third-generation EGFR-TKI, is an original drug developed by a Shanghai Allist Pharmaceuticals. Furmonertinib is a potent irreversible inhibitor of EGFR that specifically targets mutations in the receptor. It is effective against two types of mutations: resistance mutations (T790M) and activating mutations (L858R and exon 19 deletions). Furmonertinib is more effective at inhibiting tumor cells with these mutations compared to cells with the normal, wild-type EGFR. In the FURLONG study, a randomized Phase III trial that included previously untreated advanced NSCLC patients with EGFR-sensitive mutations, furmonertinib demonstrated superior PFS compared to gefitinib. The PFS achieved with furmonertinib was numerically longer than that observed with other third-generation EGFR-TKIs such as osimertinib and almonertinib, making it the longest achieved PFS to date.
 
Furmonertinib has shown encouraging antitumor activity and CNS activity in patients with advanced NSCLC with EGFR ex20ins. Moreover, furmonertinib had a good safety profile and no dose-dependent toxicity. Furmonertinib 160 mg is an optional regimen for patients with advanced NSCLC who develop resistance after treatment with third-generation EGFR-TKIs, especially those developing resistance due to the progression of intracranial lesions, with good efficacy and an acceptable safety profile that warrants further exploration.